Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Theriva Biologics Inc TOVX

Healthcare Biotechnology
Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. It is advancing a new oncolytic adenovirus platform. Its candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01 is an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade... see more

Recent & Breaking News (NYSEAM:TOVX)

Theriva(TM) Biologics Reports Third Quarter 2024 Operational Highlights and Financial Results

GlobeNewswire 11 days ago

Theriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech Grant

GlobeNewswire October 31, 2024

Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma

GlobeNewswire October 16, 2024

Theriva(TM) Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

GlobeNewswire October 3, 2024

Theriva Biologics Announces Pricing of $2.5 Million Public Offering

GlobeNewswire September 26, 2024

Theriva(TM) Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

GlobeNewswire September 23, 2024

Theriva(TM) Biologics Awarded Manufacturing Funding from the Spanish Government's National Knowledge Transfer Program

GlobeNewswire September 16, 2024

Theriva Biologics Announces Reverse Stock Split

GlobeNewswire August 16, 2024

Theriva(TM) Biologics Reports Second Quarter 2024 Operational Highlights and Financial Results

GlobeNewswire August 13, 2024

Theriva(TM) Biologics Receives Rare Pediatric Drug Designation by the U.S. FDA for VCN-01 for the Treatment of Retinoblastoma

GlobeNewswire July 31, 2024

Theriva(TM) Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer

GlobeNewswire May 23, 2024

Theriva(TM) Biologics to Participate in the A.G.P. Virtual Healthcare Conference

GlobeNewswire May 14, 2024

Theriva(TM) Biologics Reports First Quarter 2024 Operational Highlights and Financial Results

GlobeNewswire May 7, 2024

Theriva(TM) Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire April 25, 2024

Theriva(TM) Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma

GlobeNewswire April 23, 2024

Theriva(TM) Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting

GlobeNewswire April 22, 2024

Theriva(TM) Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting

GlobeNewswire April 8, 2024

Theriva(TM) Biologics Reports Full-Year 2023 Operational Highlights and Financial Results

GlobeNewswire March 25, 2024

Theriva(TM) Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial Results

GlobeNewswire March 19, 2024

Theriva(TM) Biologics to Participate in the BIO-Europe Spring Conference

GlobeNewswire March 11, 2024